Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

Bristol Myers Squibb’s Camzyos sales surged 74% YoY to $729M in 1H 2026, and the FDA accepted a supplemental NDA for adolescent (12 to <18) oHCM with Priority Review (target action date Sept. 30, 2026). However, BMY’s milvexian program faced a late-2025 setback after discontinuing the phase III Librexia ACS study. The article also notes BMY shares are up 25.3% YTD and that 2026 EPS estimates rose to $6.86 from $6.34 over the past 30 days, supporting a modestly positive outlook despite ongoing pipeline volatility.

Analysis

This is more a quality-of-revenue story than a size-of-revenue story. The adolescent label path is incremental for BMY, but the real market question is whether it extends the HCM funnel enough to slow the patent-cliff narrative; by itself it probably does not. The second-order benefit is to the entire sarcomere-inhibitor category: more awareness, more diagnosis, and more echo/clinic throughput can lift utilization across BMY and CYTK, but the commercial winner is likely to be the company that already owns prescribing habits and payer relationships.

Near term, the Sept. 30 FDA decision is a binary catalyst, but the stock reaction should fade unless management can show this is pulling forward a materially larger patient base or better persistence. The main reversal risks are a narrower-than-expected label, added safety/monitoring burden that slows uptake, or a headline-approved indication that proves too small to move consensus estimates. Over 1-3 months, the bigger driver remains whether the market starts to believe BMY’s non-Eliquis growth can offset erosion; if not, this becomes just another niche expansion in a still-discounted multiple.

Contrarian take: consensus may be overrating BMY’s competitive position in HCM and underestimating CYTK’s first-mover advantage. Once one agent becomes the default in a specialty market, switching costs are mostly behavioral and formulary-driven, not scientific, so BMY may need a better launch execution than the market expects. The true structural catalyst is still milvexian/Librexia; without clean data there, Camzyos is additive but not thesis-changing for 6-18 months.

Key Decisions for Investors

• Prefer CYTK over BMY into the Sept. 30 FDA window: long CYTK / short BMY as a relative-value HCM pair if BMY rallies on label-expansion speculation. Risk/reward favors the company with the cleaner commercial monopoly and less dependence on an offset to patent erosion; thesis breaks if BMY wins an unexpectedly broad adolescent label and immediate payer coverage.
• Avoid chasing BMY on approval headlines; if anything, use a post-event pop to fade into strength unless management updates imply a meaningful step-up in HCM penetration. This is a months-long catalyst, not a multi-year earnings reset.
• Set a watch item on Librexia AF and stroke data: BMY’s real re-rating trigger is a credible replacement path for future Eliquis decay. If AF data slip again or look merely non-inferior without commercial differentiation, use any BMY rally as an exit opportunity.
• For event-driven accounts, consider a small BMY call spread only on pullbacks ahead of the FDA date, not outright stock. The upside is capped by the small addressable adolescent cohort, while downside is limited by already-existing adult sales momentum; falsify if the label is delayed, narrowed, or accompanied by a burdensome monitoring requirement.